Dr. Kleanthis Xanthopoulos, co-founder,  Chairman  and CEO of Shoreline Biosciences, discusses the development of genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer (NK) and macrophage products that are intelligently designed for greater  specificity, potency and persistence, overcoming the limitations of early cell therapies, for use in oncology and regenerative medicine. Kleanthis is a serial […]

Dr Seth Lederman is a physician-scientist, entrepreneur, and CEO of Tonix Pharmaceuticals. He talks to Lu Rahman about Tonix Pharmaceuticals’ mission to research and manufacture small molecules and biologics for the treatment of CNS and immunological conditions.  Since its formation in 2011, Tonix Pharmaceuticals has harnessed the power of clinical research and strategic collaborations to develop novel in-house and in-licensed compounds for […]

Shoreline Biosciences secured $140 million in financing to accelerate the growth of its induced pluripotent stem cells (iPSC)-based immunotherapies and support the expansion of its manufacturing capabilities. The financing round comes hot off the heels of two partnerships the company struck this summer valued at $4 billion. Shoreline entered into collaborations with Kite Pharmaceuticals, a Gilead Sciences company, and BeiGene. […]